| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Charles A Rowland Jr. is Director at GBIO and has filed Form 4s across 2 companies. Charles A Rowland Jr.'s net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Historically, Charles A Rowland Jr.'s trades have earned a below-average insider score of 49/100 across 9 rated trades. Over a 12-month horizon, 22.2% of those trades were profitable, with an average 12-month return of -20.8%.
The biggest single holding is VKTX (~$865K) as Director. The VKTX filings lean toward selling, a net 70,000 shares.
Charles A Rowland Jr. has 25 Form 4 filings on record from July 2017 to January 2026, across 2 companies: Director at Viking Therapeutics (VKTX), 2017–2026; Director at Generation Bio (GBIO), 2020–2025.
The 34 reported transactions were 16 option or other derivative awards, 10 open-market purchases, 4 stock awards and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 7 purchases worth about $2.2M and 2 sales worth about $3.1M.
The largest open-market purchase was 30,000 shares of GBIO at an average $19.00 on June 16, 2020, about $570K.
The largest open-market sale was 60,000 shares of VKTX at an average $35.57 on October 27, 2025, about $2.1M. Twelve months later VKTX was down 31%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE | 60,000 | $35.57 | $2,134,278.00 | -66.7% | -11.7% | -30.7% | |
| Dec 4, 2023 | GBIO Generation Bio Co. | Director | Buy | 342,960 | $1.39 | $477,777.60 | +178.8% | +82.8% | -9.3% | |
| May 16, 2023 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE | 40,000 | $25.00 | $1,000,000.00 | -57.1% | -40.4% | +216.5% | |
| Sep 19, 2022 | GBIO Generation Bio Co. | Director | Buy | 15,750 | $5.26 | $82,845.00 | +8.9% | -20.2% | -22.1% | |
| Sep 16, 2022 | GBIO Generation Bio Co. | Director | Buy | 50,628 | $5.46 | $276,241.15 | +40.4% | -17.9% | -25.9% | |
| Sep 14, 2022 | GBIO Generation Bio Co. | Director | Buy | 24,384 | $5.22 | $127,403.94 | +24.1% | -8.3% | -22.7% | |
| Jan 11, 2021 | GBIO Generation Bio Co. | Director | Buy | 20,408 | $24.50 | $499,996.00 | +25.3% | - | - | |
| Jun 16, 2020 | GBIO Generation Bio Co. | Director | Buy | 30,000 | $19.00 | $570,000.00 | +59.3% | - | - | |
| May 29, 2018 | VKTX Viking Therapeutics, Inc. | Director | Buy | 30,000 | $5.16 | $154,800.00 | New | - | - |